<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049190</url>
  </required_header>
  <id_info>
    <org_study_id>ARN-AR18-CT-102</org_study_id>
    <nct_id>NCT02049190</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arno Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arno Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, parallel group two-stage phase 1-2 study with an&#xD;
      escalation and an expansion component. This study will evaluate an extended-release (ER)&#xD;
      formulation of onapristone in patients with prostate cancer in which Progesterone Receptor&#xD;
      (PR) may be contributing to tumor progression. A companion diagnostic to select patients&#xD;
      whose prostate cancer expresses the activated form of the PR (APR) is under development and&#xD;
      will be implemented in this study; it may be used to further enrich the selection of the&#xD;
      population based upon ongoing review of the results. Patients will be treated until&#xD;
      occurrence of an intolerable safety issue, treatment failure, if patient elects to withdraw,&#xD;
      or for non-compliance with either protocol-specified evaluations or onapristone treatment. An&#xD;
      additional cohort of patients will be included at the recommended phase 2 dose to gain&#xD;
      additional understanding of the onapristone safety profile and potential anti-cancer&#xD;
      activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities related to onapristone or the combination of onapristone and abiraterone utilizing a day 57 safety cut off and based on CTCAE v4</measure>
    <time_frame>Baseline to 57 days post-first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to onapristone or the combination of onapristone and abiraterone</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
    <description>Objective partial or complete response by RECIST 1.1, confirmed on a second CT scan at least 4 weeks apart and / or&#xD;
PSA decline of ≥ 50% (according to the PCWG2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of extended-release onapristone tablets BID</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
    <description>Safety will be assessed by physical exam, vital signs, monitoring of adverse events, changes in ECG, and changes in PSA and other clinical laboratory values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of onapristone, mono-demethylated onapristone and other metabolites in plasma and urine</measure>
    <time_frame>Baseline to 30 Days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Androgen-independent Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>onapristone 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 10 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 20 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 30 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 40 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 40 mg BID extended-release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>onapristone 50 mg BID extended-release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 30 mg BID + abiraterone 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onapristone 50 mg BID + abiraterone 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort: onapristone 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort: onapristone 50 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onapristone</intervention_name>
    <arm_group_label>Expansion cohort: onapristone 50 mg BID</arm_group_label>
    <arm_group_label>onapristone 10 mg BID</arm_group_label>
    <arm_group_label>onapristone 20 mg BID</arm_group_label>
    <arm_group_label>onapristone 30 mg BID</arm_group_label>
    <arm_group_label>onapristone 30 mg BID + abiraterone 1000 mg</arm_group_label>
    <arm_group_label>onapristone 40 mg BID</arm_group_label>
    <arm_group_label>onapristone 50 mg BID</arm_group_label>
    <arm_group_label>onapristone 50 mg BID + abiraterone 1000 mg</arm_group_label>
    <other_name>ZK 98299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone</intervention_name>
    <arm_group_label>onapristone 30 mg BID + abiraterone 1000 mg</arm_group_label>
    <arm_group_label>onapristone 50 mg BID + abiraterone 1000 mg</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male patients, 18 years of age or greater;&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the prostate (without neuroendocrine&#xD;
             differentiation or small cell features);&#xD;
&#xD;
          3. In Stage 2, a mandatory biopsy is required with confirmed PR or APR in ≥1% tumor&#xD;
             cells. For patients recruited to the abiraterone-onapristone combination arm, the&#xD;
             biopsy must be performed on abiraterone administered as the most recent treatment and&#xD;
             after a minimum of 2 weeks continuous treatment. For other patients, the biopsy must&#xD;
             be taken at progression on or after abiraterone or enzalutamide or before screening&#xD;
             with no anti-cancer treatment taken in the intervening period and a maximum of six (6)&#xD;
             months prior to study start. If archival tissue is also available this should be&#xD;
             provided for comparison purposes; a paired biopsy at day 8-28 is optional;&#xD;
&#xD;
          4. Metastatic or recurrent inoperable disease after previous surgery, radiation therapy,&#xD;
             and/or chemotherapy;&#xD;
&#xD;
          5. For patients in Stage 1 and for patients in Stage 2 who will receive combination&#xD;
             therapy with onapristone and abiraterone: no more than one prior chemotherapy regimen&#xD;
             for CRPC (docetaxel rechallenge will be regarded as one line of chemotherapy); for&#xD;
             patients in Stage 2 who will receive onapristone monotherapy: no prior chemotherapy is&#xD;
             allowed;&#xD;
&#xD;
          6. Disease that has progressed by PSA or radiologically, on abiraterone or enzalutamide.&#xD;
             Disease progression for study entry is defined as one or both of:&#xD;
&#xD;
               -  PSA progression defined by a minimum of two rising PSA levels with an interval of&#xD;
                  ≥1 week between each determination.&#xD;
&#xD;
               -  Radiological progression per RECIST 1.1;&#xD;
&#xD;
          7. For patients recruited to the abiraterone-onapristone combination arm, progression on&#xD;
             abiraterone as their last line of treatment is required after a prior response to&#xD;
             abiraterone;&#xD;
&#xD;
          8. The PSA value at screening and baseline should be ≥ 2 µg/L (2 ng/mL);&#xD;
&#xD;
          9. For onapristone monotherapy, corticosteroid discontinuation &gt;4 weeks or &gt;2 weeks with&#xD;
             normal adrenal function confirmed by an ACTH stimulation test. For the combination&#xD;
             onapristone - abiraterone arm, prednisolone 5mg BID and no other steroid regimen&#xD;
             allowed for 2 weeks prior to treatment initiation;&#xD;
&#xD;
         10. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH)&#xD;
             analogue or orchiectomy (i.e., surgical or medical castration);&#xD;
&#xD;
             • For patients who have not had an orchiectomy, there must be a plan to maintain&#xD;
             effective GnRH-analogue therapy for the duration of the trial;&#xD;
&#xD;
         11. Serum testosterone level &lt; 1.7 nmol/L (50 ng/dL);&#xD;
&#xD;
         12. Patients receiving bisphosphonate therapy must have been on stable doses for at least&#xD;
             4 weeks;&#xD;
&#xD;
         13. Evaluable disease per RECIST 1.1 [Eisenhauer 2009] or Prostate Cancer Clinical Trials&#xD;
             Working Group 2 (PCWG2) [Scher 2008];&#xD;
&#xD;
         14. ECOG performance status 0-2;&#xD;
&#xD;
         15. Life expectancy ≥ 3 months;&#xD;
&#xD;
         16. Willing and able to sign written informed consent per ICH-GCP, the local regulatory&#xD;
             requirements, and local data protection laws prior to study-specific screening&#xD;
             procedures.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Serum creatinine &gt;1.5 ULN;&#xD;
&#xD;
          2. On ECG a QTc(F) interval &gt;480 msec or any clinically significant cardiac rhythm&#xD;
             abnormalities;&#xD;
&#xD;
          3. Liver function tests documented within the screening period and/or at baseline:&#xD;
&#xD;
               1. Total bilirubin &gt; ULN (except in patients diagnosed with Gilbert's disease);&#xD;
&#xD;
               2. Alkaline phosphatase &gt; 2.5 x UNL, unless test for alkaline phosphatase isoenzymes&#xD;
                  is elevated only for bone isoenzyme;&#xD;
&#xD;
               3. ALT/AST &gt; UNL or &gt; 2.5 x UNL in case of liver metastases;&#xD;
&#xD;
          4. Absolute neutrophil count &lt; 1,500/µL, platelet count &lt; 100,000/µL, and hemoglobin &lt;&#xD;
             5.6 mmol/L (9 g/dL) and no growth factors or blood transfusions within 7 days of these&#xD;
             values;&#xD;
&#xD;
          5. Serum albumin &lt; 25 g/L (2.5 g/dL);&#xD;
&#xD;
          6. Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2,&#xD;
             hepatitis B (surface antigen), or hepatitis C (testing not required);&#xD;
&#xD;
          7. Chronic inflammatory liver condition. History or clinical evidence of any liver or&#xD;
             biliary pathology including cirrhosis, infectious disease, inflammatory conditions,&#xD;
             steatosis, or cholangitis (including ascending cholangitis, primary sclerosing&#xD;
             cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of&#xD;
             Oddi, biliary cyst or biliary atresia;&#xD;
&#xD;
          8. Patients with any other prior malignancy are not allowed except for:&#xD;
&#xD;
               1. Adequately treated basal cell or squamous cell skin cancer;&#xD;
&#xD;
               2. Adequately treated Stage I or II cancer from which the patient is currently in&#xD;
                  complete remission;&#xD;
&#xD;
               3. Other cancer from which the patient has been disease-free for 2 years;&#xD;
&#xD;
          9. For Stage 1 only: Chronic adrenal failure or is receiving concurrent long-term&#xD;
             corticosteroid therapy. Prior long-term corticosteroids must be stopped ≥4 weeks or &gt;2&#xD;
             weeks if normal adrenal function is confirmed by an ACTH stimulation test prior to&#xD;
             start of study drug;&#xD;
&#xD;
         10. History or clinical evidence of any surgical or medical condition which the&#xD;
             investigator judges as likely to interfere with the results of the study or pose an&#xD;
             additional risk in participating; e.g., active or clinically significant history of&#xD;
             disease involving a major organ system-vascular, cardiac, uncontrolled hypertension,&#xD;
             pulmonary, gastrointestinal, hematologic, neurologic, neoplastic, renal, endocrine or&#xD;
             immunodeficiency, or clinically significant active psychiatric disorders;&#xD;
&#xD;
         11. Used any prescription medication during the prior 2 weeks that the investigator judges&#xD;
             is likely to interfere with the study or to pose an additional risk to the patient in&#xD;
             participating, specifically inhibitors or inducers of cytochrome P450 (CYP)3A4 (see&#xD;
             Appendix 4);&#xD;
&#xD;
         12. Received an investigational product or been treated with an investigational device&#xD;
             within 30 days prior to first drug administration, or plans to start any other&#xD;
             investigational product or device study within 30 days after last drug administration;&#xD;
&#xD;
         13. Received prior therapies within the following time period prior to receipt of first&#xD;
             dose of study drug (Day 1, without withdrawal response and with no plans to initiate&#xD;
             any of these during study:&#xD;
&#xD;
               1. Ketoconazole or bicalutamide within 6 weeks;&#xD;
&#xD;
               2. Systemic hormone therapy, chemotherapy, targeted therapies, antibodies within 4&#xD;
                  weeks excluding abiraterone in the abiraterone-onapristone combination arm;&#xD;
&#xD;
               3. Fractionated radiotherapy within 3 weeks;&#xD;
&#xD;
               4. Single fraction of radiotherapy within 2 weeks;&#xD;
&#xD;
               5. Radionuclide therapy within 8 weeks;&#xD;
&#xD;
               6. Brachytherapy Pd-103 implant within the last 3 months;&#xD;
&#xD;
               7. Brachytherapy I-125 implants within 12 months.&#xD;
&#xD;
         14. Concurrent use of herbal products that may decrease PSA levels (e.g., saw palmetto);&#xD;
&#xD;
         15. Residual toxicity of prior anticancer treatment &gt; grade 1 except for alopecia;&#xD;
&#xD;
         16. Brain metastases, active epidural disease or spinal cord compression, unless treated&#xD;
             at least 4 weeks before entry, and stable with steroid treatment for ≥1 week;&#xD;
&#xD;
         17. Paget's disease of the bone;&#xD;
&#xD;
         18. Structurally unstable bone lesions suggesting impending fracture;&#xD;
&#xD;
         19. Patients with reproductive potential not employing adequate contraception during&#xD;
             treatment and for 1 month after completing treatment;&#xD;
&#xD;
         20. Lack of physical integrity of the upper gastrointestinal tract, malabsorption&#xD;
             syndrome, or inability to swallow pills;&#xD;
&#xD;
         21. Mental incapacity or language barriers precluding adequate understanding,&#xD;
             co-operation, and compliance with the study requirements;&#xD;
&#xD;
         22. Is, in the judgment of the investigator, unable or unwilling to comply with the&#xD;
             requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alice S Bexon, MD</last_name>
    <phone>1-617-417-7300</phone>
    <email>alice.bexon@bexonclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inst of Cancer Research &amp; Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton Surrey</city>
        <zip>SH2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhardt Attard, MD, PhD, MRCP</last_name>
      <phone>(+44) 020 872224137</phone>
      <email>gerhardt.attard@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Johann S De Bono, MD, PhD, MSc, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquin Mateo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Prostate Cancer</keyword>
  <keyword>Castration-resistant Prostate Cancer</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Genital Neoplasms, Male</keyword>
  <keyword>Urogenital Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Genital Diseases, Male</keyword>
  <keyword>Prostatic Diseases</keyword>
  <keyword>onapristone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onapristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

